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Background: TB pneumonia may be associated with 
hemodynamic instability in 10% of cases being needed 
urgently initiate TB therapy once the diagnosis is made, 
however the situation can be complicated by the presence 
of drug-induced liver toxicity, unable to establish which of 
the drugs of first line is the cause of the situation. The aim 
of this study is to describe in these patients, the clinical 
behavior and smear findings after the first month of 
treatment with pharmacological unconventional schemes. 
 
Design/Methods: Information of 36 patients admitted to 
intensive care in western Colombia between January 2003 
and December 2013 due TB pneumonia and drug toxicity to 
first-line drugs is collected.  
Results: Following the initiation of conventional therapy 
90% of patients presented elevation of more than 5 times 
the normal value in the level of liver enzymes, the 
remaining 10% the value was between 3 and 5 times, 
hyperbilirubinemia document in all cases; the time to onset 
of toxicity was 8 days on average and in all cases the tests 
normalized after the withdrawal of the scheme ; the 
combination of moxifloxacin, aminoglycoside and eth-
ambutol was used in 32 cases, in the remaining 2 
ethambutol was excluded ; the average prescription time 
while hemodynamic stability was achieved and the cause of 
drug toxicity was established replacement was 28 days ; 
toxicity was secondary to pyrazinamide in 55%, whereas 
isoniazid and rifampicin in 30 and 15% respectively ; the 
time of mechanical ventilation had a mean of 9 days; 2 
patients died ;the smear was positive in 4 patients after the 
term of unconventional scheme;in all patients conven-tional 
scheme is restart once were in hemodynamic stability and 
removing the causative drug toxicity.  
Conclusion: The severity of hemodynamic and respirato-ry 
compromise in patients following TB pneumonia re-
quiresdrugalternatives in situations in which drug toxicity 
appears to conventional antituberculosis drugs , this is 
based on the impact may cause the delay of antibiotic 
therapy in patients with critical condition. The combina-tion 
of moxifloxacin, aminoglycoside, ethambutol is pre-sented 
as a therapeutic alternative in patients whose con-dition can 
not tolerate delays in initiation of treatment. 
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Introduction Tuberculosis is one of the main causes of 
morbidity and mortality in different societies. In 2010, 
 
 
there were an estimated 12 million people living with active 
TB, including 8.8 million new cases and there were an 
estimated 1.4 million deaths. Identifying causes for death 
following diagnosis of TB is important for planning 
effective interventions to reduce death rates. The aim of this 
study was to assess and determinate main causes of death in 
TB patients in our Institute.  
Materials and methods It is a retrospective descriptive study 
conducted in Institute for lung diseases and tuberculosis, 
Skopje, Macedonia, from 2010 to 2013. Medical records of 
died tuberculosis patients over 4 – year period were 
reviewed and death data were analyzed. Results Twenty 
two deaths ( 15% from all hospitalized patients ) with mean 
age of 58þ/- 10.3 years were detected, 69.6% were male 
and 30,4% were female. The frequency rate for cigarette 
smoking, alcoholism, diabe-tes, intravenous drug usage, as 
risk factors were 54.5%, 22.7%, 4.5% and 4.5% 
respectively. 12 deaths ( 54,5%) were directly attributed to 
tuberculosis, among them overwhelming TB disease with 
respiratory failure, massive hemoptysis and MDR-TB 
accounted as the cause of death in 75%, 8.3% and 16.6% 
respectively. 10 deaths (45,5%) were due to other medical 
problems, which included, COPD, cardiovascular diseases, 
high blood pressure, cirrhosis, dementia i.e. 18.2%, 31.8%, 
18.2%, 4.5% and 4.5% respectively. The median time of 
survival was 28 days. 77.2% of patients died during the 
initial-2- month intensive phase of anti - TB treatment. 
36.4% died in the first 10 days of treatment. Those who 
died of tuberculosis had statistically significant (p, 0.001) a 
shorter median survival ( 14,9 ) days in comparison with 
group who had other medical problems ( 27days ). 
 
 
Conclusion This study showed that overwhelming TB 
disease, with respiratory failure, haemoptysis, cardio-
vascular diseases, COPD, cirrhosis are main cases of death. 
Smoking, alcoholisms, diabetes, intravenous drug usage are 
frequent risk factors for TB mortality. 
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Background: Tuberculosis (TB) control is complicated by 
the interaction of the TB and human immunodeficiency 
virus (HIV) epidemics, yet participation of HIV-infected 
patients in TB treatment trials is often limited. Reasons for 
this include drug-drug interactions amongst antiret-roviral 
and antituberculous agents, overlapping drug toxicities, and 
concerns about increased morbidity and mortality from the 
HIV disease, all of which may 
 
